AI in Drug Discovery Funding Tracker (144 deals)

Our funding tracker covering the AI in drug discovery market

Below is the table listing all the deals. You may find our methodology at the end of this page.

And, if you want to gain a deeper understanding of the market and its current dynamics, get our report covering the AI In Drug Discovery Market.

Is AI drug discovery actually a big funding market right now?

AI drug discovery funding is big in dollars today, but a typical company sees nothing close to the giant checks that dominate the headlines.

From January 2024 through our cutoff, we tracked 144 qualifying financings across 116 companies and at least $8.64 billion of calculable capital. The median round was $14.2 million. The average was $60.4 million.

That is a huge gap. A relatively small number of very large rounds pull the average far above what most startups actually raise.

Strip out financings above $50 million and the capital total falls to about $2.02 billion. Most AI drug discovery startups are playing in a market measured in single-digit or low-double-digit millions; a much smaller group has reached a financing scale closer to serious biotechnology development.

Market snapshot	Result
Qualifying financings	144
Unique companies	116
Calculable capital	≥$8.64B
Median round	$14.2M
Average round	$60.4M
Average / median	4.25x
Capital excluding >$50M rounds	$2.02B
Companies with multiple rounds	24

How many AI drug discovery companies are actually getting funded?

AI drug discovery funding reaches a fairly broad group of companies, but repeat fundraising is already separating a small group from everyone else.

We found 116 companies behind the 144 financings. Ninety-two companies appear only once during the period, while 24 raised at least twice.

That means 79.3% of the funded companies show up only once.

Some of that comes down to timing. A startup that first raised in 2026 has had much less time to return than one funded in early 2024. Still, a 20.7% repeat-fundraising rate is low enough to show that raising once and becoming repeatedly fundable are very different achievements in this market.

The financial split is even clearer. Companies that raised more than once collected about $5.13 billion, versus roughly $3.51 billion for the much larger group that appears only once.

Plenty of companies can get into the AI drug discovery funding market. Far fewer manage to keep climbing.

Is most AI drug discovery money going to just a handful of startups?

AI drug discovery funding is extremely concentrated: five companies hold about 63% of the calculable capital we tracked.

Isomorphic Labs accumulated $2.70 billion across two financings. Xaira Therapeutics launched with at least $1 billion of committed capital. Earendil Labs raised $787 million. Chai Discovery accumulated $630 million across four rounds, while Enveda reached $335 million across three.

The top ten companies together account for 73.1% of capital.

Company-level concentration is especially revealing because repeat fundraising compounds the gap. Chai, Enveda, Isomorphic and several other companies returned for additional rounds while most companies raised once.

At the lower end, 22 of the 115 companies for which cumulative capital can be calculated never moved above $5 million during the period.

Calling all of these companies part of the same funding market is technically correct, but their financial realities are worlds apart.

Company	Qualifying capital	Rounds
Isomorphic Labs	$2.70B	2
Xaira Therapeutics	≥$1.00B	1
Earendil Labs	$787M	1
Chai Discovery	$630M	4
Enveda	$335M	3
Syneron Bio	~$250M	2
Superluminal Medicines	$180M	2
Aureka Biotechnologies	$158.2M	3
Iambic Therapeutics	>$150M	2
Insilico Medicine	$123M	2

What can a normal AI drug discovery startup realistically raise today?

For most AI drug discovery startups, a realistic financing is somewhere in the millions or tens of millions of dollars, with $14.2 million sitting at the middle of the market.

We counted 30 rounds below $5 million, 47 between $5 million and $20 million, and another 40 between $20 million and $50 million. Those three brackets alone contain more than four-fifths of all financings.

Only 15 deals reached $100 million or more.

Stage changes the benchmark quickly. The median Seed round was $7 million. Series A moved up to $25 million, while Series B reached $60 million.

For a founder trying to work out what a "normal" raise looks like these days, the $60.4 million market average is a pretty bad reference point. A $5 million to $30 million round is much closer to the financing environment most companies actually encounter.

Are mega-rounds making AI drug discovery look much bigger than it really is?

Yes. Mega-rounds have a huge effect on AI drug discovery funding totals, with 22 financings above $50 million taking 76.6% of all calculable capital.

Those 22 deals represent only 15.3% of the financing count.

Go one step higher and the concentration becomes even more obvious. Rounds above $100 million represent 8.3% of deals while absorbing 67.1% of capital.

Isomorphic Labs provides the clearest example. Its $2.1 billion Series B alone accounts for roughly one-quarter of the entire capital total. The round also turned one month into a $2.121 billion funding peak, even though monthly deal activity itself never moved nearly as violently.

Across the 32 completed months we studied, the median month contained four financings and the busiest months contained eight. Deal activity at the peak was therefore only twice the median. Capital at its peak was 16.7 times the median monthly amount.

A monthly funding chart can make AI drug discovery look as if the whole market suddenly exploded. Usually, one or two companies explain most of the jump.

Which part of AI drug discovery is actually getting the money?

De Novo Design is where serious AI drug discovery capital is concentrated today, with about $6.67 billion flowing into the category.

We classified 64 financings across 48 De Novo Design companies. That gives the category 44% of the deals but 77.2% of the capital.

AI Lead Generation sits a long way behind at $868.4 million. Target Discovery has more deals than Lead Generation, yet attracts only $458.2 million.

The median figures show the gap goes beyond one or two famous rounds. A De Novo Design financing has a $24.6 million median, the highest among the major categories we tracked.

Target Discovery is the cleanest counterexample. It generated 25 deals, or around one-sixth of the whole dataset, but attracted only 5.3% of the money.

Funding activity is spread across different parts of AI drug discovery. Big checks are much more selective.

Category	Deals	Companies	Capital	Median round
De Novo Design	64	48	$6.67B	$24.6M
AI Target Discovery	25	21	$458.2M	$12.0M
AI Lead Generation	22	19	$868.4M	$14.5M
Preclinical Prediction AI	14	12	$233.9M	$17.4M
AI Lead Optimization	13	13	$275.0M	$8.9M
AI Drug Repurposing	6	4	$132.0M	$17.0M
Total market	144	116	≥$8.64B	$14.2M

Why are De Novo Design companies raising so much more money?

De Novo Design companies are raising bigger rounds because the leading businesses increasingly combine AI models, experimental science and actual drug programs under one roof.

Isomorphic Labs makes the pattern easy to see. When the company announced its latest funding, it said the money would support continued development of its AI drug design engine, international expansion and therapeutic programs moving toward the clinic. Its earlier $600 million round was framed in much the same way.

Earendil Labs said its $787 million financing would expand its AI R&D platform and advance a pipeline of antibody and biologics programs. Enveda's $150 million Series D was tied to clinical development, including Phase 1b and Phase 2 work and additional IND filings.

Chai Discovery offers another version of the model. It moved from a Seed round to a $70 million Series A, a $130 million Series B and a $400 million Series C in less than two years. Around the same period, it announced drug-discovery work with Novartis, argenx and Bristol Myers Squibb.

These businesses need computational infrastructure, but compute is only part of the bill. Scientists, proprietary datasets, wet-lab experiments, screening, molecule development, regulatory work and clinical programs all add up quickly.

That is why the biggest AI drug discovery rounds increasingly resemble biotech financing in size.

Is AI drug discovery still mainly an early-stage market?

AI drug discovery is still an early-stage market by deal count, even though most of the capital already sits further up the funding ladder.

Seed and Series A account for 102 of the 129 financings where we could classify the stage. That is 79.1% of classified deals.

The money looks very different. Later-stage financings take 53.3% of classified capital, despite representing only 20.9% of the deals.

Cheque sizes rise fast as companies progress. The median moves from $7 million at Seed to $25 million at Series A, $60 million at Series B and $88.5 million at Series C.

That is a familiar biotech dynamic showing up inside an AI market: many companies can be funded while the science is young, but the companies that survive into asset development need much more money.

Stage	Deals	Companies	Capital	Median deal
Seed	57	52	$618.8M	$7.0M
Series A	45	43	$2.927B	$25.0M
Series B	17	16	$3.174B	$60.0M
Series C	4	3	$579M	$88.5M
Series D+	4	3	$278.1M	$61.5M
Growth Equity	2	2	$16.4M	$8.18M
Unknown	15	15	$1.046B	$13.3M

Where does AI drug discovery funding start to break down?

AI drug discovery funding starts getting much harder after Series A, with the number of financings dropping sharply once companies need Series B-scale capital.

We counted 57 Seed rounds and 45 Series A rounds, so the first step of the ladder remains relatively broad.

Series B is where the population thins out. There are only 17 Series B financings for 45 Series As, a 2.65-to-one difference.

Then it tightens again. Only four Series C financings appear during the full period.

These figures should not be treated as literal conversion rates. Companies entered our window at different times, many had earlier rounds before 2024, and a company financed recently may simply need more time before raising again.

Even with that caveat, the shape is hard to miss. Finding investors for an early scientific thesis happens fairly often. Convincing investors to put $50 million, $100 million or more behind the next phase is where the field gets much smaller.

Why are Series C rounds still so rare in AI drug discovery?

Series C funding remains rare in AI drug discovery because investors have only a small pool of companies with enough scientific and commercial proof to justify that scale of financing.

By this point, a promising model or a compelling founding team is usually not enough. Investors can look for evidence that designed molecules work experimentally, that the platform can repeat its results, that pharma companies want to use it, or that owned drug programs are moving through development.

Enveda is a good example of that progression. The company paired its later financing with clinical advancement of ENV-294 and subsequently moved the program further through clinical development.

Chai took a different route. Its fast fundraising progression came alongside increasingly concrete deployment with major pharmaceutical groups, while its own molecular-design models moved from research releases toward commercial drug-discovery use.

Iambic offers another useful marker. Its financing of more than $100 million followed clinical data for IAM1363 and came as the company was expanding its own pipeline and external drug-discovery collaborations.

These are very different businesses, but by the time serious later-stage money arrives, investors are seeing more than an AI demonstration. They can see a path toward medicines, revenue, valuable partnerships or all three.

How young are AI drug discovery companies when the big checks arrive?

AI drug discovery companies can reach serious financing surprisingly fast, with a median age of only four years among companies raising more than $50 million.

Across all financings, the median company age was three years.

The progression by stage looks intuitive: two years at Seed, four at Series A, six at Series B and 7.5 at Series C. Series D+ companies have a median age of ten years.

What is more striking is the founding-year mix. Much of the funded population was created very recently: 24 companies were founded in 2021, 19 in 2022, 22 in 2023 and 21 in 2024.

The market today is being built largely by a new generation of AI-native or AI-first biotech companies. Some can move from formation to very large rounds within only a few years when the technical and scientific progress is fast enough.

Is AI drug discovery funding creating new companies or backing existing winners?

AI drug discovery funding currently leans heavily toward companies investors already know, with 72.9% of the financings classified as follow-on rounds.

We counted 105 follow-on financings, 38 first financings and one case where the status could not be established confidently.

Follow-on rounds are also larger. Their median is $21 million, compared with $10 million for first financings.

In total, follow-ons account for about $6.49 billion of capital.

New entrants have not disappeared. Thirty-eight companies received what we classify as their first financing during the period, so new company formation remains meaningful. The bigger flow of money is going toward companies that have already passed at least one funding test.

As funding conditions stand now, AI drug discovery looks increasingly like a selection process: investors keep creating new options at the bottom, then concentrate much more capital behind the companies that keep delivering.

Is the US still the center of AI drug discovery funding?

The US remains the deepest AI drug discovery funding market, even though Europe and Asia can look surprisingly large when we only compare headline dollars.

North America accounts for 74 financings across 60 companies and roughly $3.92 billion of capital. The US alone contributes 69 deals.

Europe reaches about $3.35 billion, which at first glance puts it surprisingly close to North America. Yet Europe's median financing is only $6.8 million, compared with $24.6 million in North America.

Isomorphic Labs explains much of the gap between the headline and the typical European deal. The company accounts for roughly 63% of European capital.

Asia-Pacific has a similar concentration problem. Earendil Labs represents around 63% of the region's roughly $1.25 billion total. In the Middle East, CytoReason accounts for the majority of the much smaller regional pool.

North America has large outliers too, especially Xaira, but its funding base is spread across far more sizeable transactions and companies.

The UK, China, Canada and France all have visible funded populations. For depth across companies, rounds and investors, the US still stands apart.

Which investors keep coming back to AI drug discovery?

AI drug discovery does not have a small club of investors repeatedly leading everything; the lead-investor market is unusually spread out.

We could identify a lead or co-lead for 109 rounds. Across those records, 133 distinct lead-investor names appear, while only 16 show up more than once.

Thrive Capital stands out because of the size of the rounds it touches. Three Thrive-led or co-led financings represent about $2.73 billion of total round value, largely because of Isomorphic Labs.

DCVC and NVentures also appear three times. Most of the other repeat names appear twice.

That mix fits the market itself. AI drug discovery sits between biotech, AI infrastructure, general venture, growth equity and pharmaceutical strategy, so different companies attract very different syndicates.

The recurring investor list exists, but it is nowhere near concentrated enough to say that a handful of funds control access to the market.

Lead or co-lead investor	Deals	Combined size of rounds
Thrive Capital	3	$2.73B
NVentures	3	$181M
DCVC	3	$141M
ARCH Venture Partners	2	$1.021B
New Enterprise Associates	2	$173.8M
General Catalyst	2	$154.6M
Granite Asia	2	$145M
Value Partners Group	2	$123M
OpenAI	2	$73M
Radical Ventures	2	$66M

Do pharma and tech companies actually matter as AI drug discovery investors?

Strategic investors matter quite a lot in AI drug discovery, especially once rounds become larger and companies move closer to real drug-development work.

We found a disclosed strategic investor in 41 of 144 financings, or 28.5%.

The difference in round size is substantial. Financings with a strategic participant have a $33 million median, compared with $10.75 million when no strategic investor is disclosed.

NVentures appears in six financings as a strategic participant, Eli Lilly in four, and AstraZeneca and OpenAI in three each. Alphabet, GV, NVIDIA, Bristol Myers Squibb and Roivant also appear repeatedly.

There is an obvious business logic behind many of these names. Pharma companies get exposure to new discovery platforms and molecules. Compute companies have an interest in workloads that consume huge amounts of advanced infrastructure.

The NVIDIA-Lilly co-innovation lab makes that convergence unusually visible. The two companies announced up to $1 billion of joint investment over five years in people, infrastructure and compute for AI-enabled drug discovery.

Strategic backing still covers a minority of rounds, but it shows up disproportionately around the part of the market where AI starts touching expensive real-world drug development.

Is AI drug discovery money moving toward software tools or actual drug programs?

The biggest AI drug discovery checks increasingly go to companies that control more of the path from model to molecule and, in many cases, from molecule toward the clinic.

We can see the pattern in the category data. De Novo Design dominates capital, while Target Discovery generates plenty of activity on much smaller checks. Preclinical Prediction also remains heavily concentrated at Seed and Series A.

The company examples make the difference easier to understand. Isomorphic is funding an AI design engine and an internal therapeutic pipeline. Enveda has moved an AI-discovered molecule through clinical development. Earendil combines its computational platform with biologics programs. Iambic is advancing its own therapeutic assets while also working with pharmaceutical partners.

Chai sits slightly differently because its platform is becoming a product that large pharmaceutical companies can use directly. Its rapid funding progression suggests investors will also pay up for a technology layer when commercial adoption becomes convincing enough.

De Novo Design already takes more than three-quarters of the market's capital. The common thread among the biggest checks is increasing control over the actual creation and development of medicines.

What does the latest AI drug discovery activity say about where the market is heading now?

Recent AI drug discovery activity points toward a tighter connection between powerful models, wet-lab validation, pharma adoption and owned therapeutic programs.

Chai is one of the clearest current examples. After raising its $400 million Series C, the company continued to announce collaborations with major pharmaceutical groups. Aureka Biotechnologies also raised $100 million in 2026 to develop biological foundation models while expanding its Lab-in-the-Loop experimental system.

Iambic has followed a similar model-to-medicine path. After raising more than $100 million, it continued building its own clinical pipeline while adding pharmaceutical collaborations, including Bayer.

The broader strategic market is moving in the same direction. NVIDIA and Lilly are jointly investing in AI infrastructure and drug-discovery research, while drugmakers are increasingly testing external AI systems inside real R&D workflows.

Not every AI drug discovery company will become a fully integrated biotech. Still, the market's attention is clearly moving toward systems that can survive contact with experimental biology and deliver something useful beyond a model benchmark.

Can we really trust the $8.64 billion AI drug discovery funding total?

The AI drug discovery funding total is best read as a careful lower-bound estimate rather than an exact measure of cash received by companies.

Several transactions make fake precision especially risky.

Xaira Therapeutics launched with more than $1 billion of committed capital. That commitment should not automatically be interpreted as a billion dollars of cash arriving on day one.

Iambic's later financing was disclosed only as more than $100 million. Beijing Scitech-MQ was reported as more than RMB100 million, which we translate into a minimum dollar amount rather than pretending we know the exact figure.

Intelligent Medicine Original, also known as AIMEDORIG, disclosed only "tens of millions of RMB." We count the financing but leave it out of calculations that require a precise amount.

Extensions, additional closes, foreign-exchange conversions, multi-tranche financings and convertibles create similar issues. We assess those case by case instead of mechanically copying the largest number in a funding headline.

Dates can require the same care. Sortera Bio publicly announced its £7.5 million pre-seed in 2025, but the company explicitly says the financing closed in May 2024. We therefore place it in 2024 when analysing financing timing.

The aggregate capital figure is pulled heavily by large transactions. Reading it as at least $8.64 billion preserves the uncertainty that genuinely exists in the underlying deals.

What should we actually take away from AI drug discovery funding today?

AI drug discovery funding today is a broad early-stage market sitting underneath a very small group of companies that can raise extraordinarily large amounts of money.

A typical financing still lives in the tens of millions rather than the hundreds of millions. Large rounds make the headline market look much richer than the experience of an ordinary startup.

Serious capital is clustering around companies that can connect computational capability with experimental biology, pharmaceutical adoption or their own drug pipeline. De Novo Design has benefited most from that shift.

The funding ladder also gets difficult fairly early. Seed and Series A activity is abundant; companies capable of sustaining B- and C-stage financing are much rarer.

Repeat fundraising is another useful dividing line. Most funded companies appear once during the period, while the smaller group that returns for more capital captures a disproportionate share of the money.

Strategic investors are now part of the market's fabric. Pharma companies, AI infrastructure providers and technology investors show up often enough, and in large enough rounds, that their involvement has become commercially meaningful.

The simplest way to understand this market is to stop treating every "AI drug discovery startup" as the same type of company. A young team raising $7 million to prove a model, a platform company selling discovery capability to pharma and a clinical-stage biotech spending hundreds of millions on drug programs may share the same label, but their capital needs and investor bases have already diverged dramatically.